Key Highlights

  • Reconsidering its September 17 delisting call, a Nasdaq Hearings Panel on October 2, 2026 cleared SCWorx to keep trading on the Nasdaq Capital Market, according to the company.
  • Shares available to the public numbered 549,092 on September 17, 2026, a sliver over the 500,000 minimum, and Nasdaq staff verified float compliance on September 30.
  • Closing levels have stayed above USD 1.00 in every session from August 4, 2026 onward, while the panel monitor runs to October 2, 2027.
  • Market data without a date showed USD 1.68, up 17.36% on 4.245 million shares; the figures are unverified.

Nasdaq Panel Changes Course on the Delisting

SCWorx (NASDAQ:WORX) sells data services to healthcare providers, spanning provider data repair and normalization, charge description master upkeep and contract administration. An October 5, 2026 company release described the panel's October 2 decision to reconsider the September 17 delisting and approve continued listing. Trading on Nasdaq had been halted since April 14, 2026, and the shares were quoted on the OTCQB during that stretch. Coverage reported Nasdaq trading resumed on October 7, which no primary document in this research confirmed. Investors should read the panel outcome as a procedural result rather than a verdict on the business.

Monitoring Terms Tied to Float and Price Tests

Conditions set by the panel are strict. SCWorx has to keep a one-year discretionary monitor running to October 2, 2027, and it must submit monthly reports covering shares outstanding, insider stakes and public float through October 5, 2027. Should it fall short of any continued listing standard during that span, no remediation window is available, and a delisting determination would follow quickly. Closing levels have stayed above the USD 1.00 mark since August 4, 2026, and each buyer in the September 2026 private Placement committed not to back out over the September 17 decision. The monthly reports are the main ongoing disclosure through October 2027.

A Thin Float Magnifies Penny Stock Risk

Secondary coverage put 2025 Revenue near USD 2.88 million and the 2025 net loss near USD 4.44 million, though neither number was matched to a filing here. An October 19, 2026 agreement with a community-owned healthcare system was also reported, with no verified financial terms. At USD 1.68 in market data, the company qualifies as a penny stock, and with a public float this small, a handful of orders can shift the price. Each trade carries extra weight in a float that thin. Quotes here can reverse quickly, and a separate report cited a 16.09% decline on October 23, 2026. Thin trading and a small float together raise the chance that any single session moves the stock sharply. Nothing here implies the 17.36% gain will continue.

Where Things Stand

The move most plausibly reflects easing listing risk, though the 17.36% gain itself is unverified. The company retained its Nasdaq place on October 2, 2026, following the September 17 decision, and works under a one-year monitor without a cure period. Given a float of only 549,092 shares, swings of this size are common in thinly traded names and do not confirm any Business change. Because the monitor runs for a year, any renewed shortfall would arrive with little warning. Monthly float reports and the next quarterly filing are the items with fixed timing to track.